Novel iron-containing phosphate binders and anemia treatment in CKD: Oral iron intake revisited

Nephrology Dialysis Transplantation

Volumn 31, Issue 10, 2016, Pages 1588-1594

  Nakanishi, Takeshi ^a   Hasuike, Yukiko ^a   Nanami, Masayoshi ^a   Yahiro, Mana ^a   Kuragano, Takahiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

anemia; hepcidin; inflammation; iron; phosphate binder

Indexed keywords

ANTIANEMIC AGENT; FERRIC HYDROXIDE; HEMOGLOBIN; IRON; PHOSPHATE BINDING AGENT; SEVELAMER CARBONATE; FERRIC CITRATE; FERRIC ION; PHOSPHATE;

ANEMIA; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTESTINE ABSORPTION; IRON ABSORPTION; IRON DEFICIENCY; IRON INTAKE; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; BLOOD; HYPERPHOSPHATEMIA; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY, CHRONIC;

ADMINISTRATION, ORAL; ANEMIA; ANIMALS; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84994807413     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv268     Document Type: Review

References (57)

1. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
2. Kooistra MP, Niemantsverdriet EC, van Es A, et al. Iron absorption in erythropoietin-Treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13: 82-88
3. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010; 6: 699-710
4. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999; 69: S61-S66
5. Johnson DW. Intravenous versus oral iron supplementation in peritoneal dialysis patients. Perit Dial Int 2007; 27 (Suppl 2): S255-S260
6. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010; 74: 4-11
7. Yokoyama K, Akiba T, Fukagawa M, et al A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 2014; 29: 1053-1060
8. Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 2015; 26: 493-503
9. Fishbane S, Kowalski EA, Imbriano LJ, et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-2657
10. Kalantar-Zadeh K, Streja E, Miller JE, et al. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 2009; 16: 143-151
11. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33
12. Nakanishi T, Hasuike Y, Otaki Y, et al. Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant 2011; 26: 3092-3100
13. Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol 2014; 307: G397-G409
14. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986-1995
15. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400
16. Schümann K, Ettle T, Szegner B, et al. On risks and benefits of iron supplementation recommendations for iron intake revisited. J Trace Elem Med Biol 2007; 21: 147-168
17. Hallberg L, Hulten L, Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Am J Clin Nutr 1997; 66: 347-356
18. Galy B, Ferring-Appel D, Becker C, et al. Iron regulatory proteins control a mucosal block to intestinal iron absorption. Cell Rep 2013; 3: 844-857
19. Conrad ME, Umbreit JN, Moore EG. Iron absorption and transport. Am J Med Sci 1999; 318: 213-229
20. Conrad ME, Weintraub LR, Crosby WH. The role of the intestine in iron kinetics. J Clin Invest 1964; 43: 963-974
21. Wheby MS, Jones LG, Crosby WH. Studies on iron absorption. intestinal regulatory mechanisms. J Clin Invest 1964; 43: 1433-1442
22. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
23. De Domenico I, Lo E, Ward DM, et al. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci USA 2009; 106: 3800-3805
24. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007; 18: 2569-2578
25. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
26. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-Analysis. Am J Kidney Dis 2008; 52: 897-906
27. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-182
28. Nakanishi T, Kuragano T, Nanami M, et al. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol 2010; 32: 439-446
29. Nakanishi T, Kuragano T, Kaibe S, et al. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012; 16: 819-826
30. Floege J, Covic AC, Ketteler M, et al A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014; 86: 638-647
31. Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J AmSoc Nephrol 2014; 9: 543-552
32. Block GA, Fishbane S, Rodriguez M, et al A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 2015; 65: 728-736
33. Yokoyama K, Akiba T, Fukagawa M, et al. Long-Term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr 2014; 24: 261-267
34. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3: 1691-1701
35. Minutolo R, Locatelli F, Gallieni M, et al. Anaemia management in nondialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013; 28: 3035-3045
36. Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014; 7: 191-201
37. Johnson BF. Hemochromatosis resulting from prolonged oral iron therapy. N Engl J Med 1968; 278: 1100-1101
38. [No authors listed]. CASE RECORDS of the Massachusetts General Hospital; case 44131. N Engl J Med 1958; 258: 652-661
39. Fleming DJ, Tucker KL, Jacques PF, et al. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort.AmJ Clin Nutr 2002; 76: 1375-1384
40. Sillerova T, Zivny J, Vyoral D, et al. Nutritional hepatic iron overload is not prevented by parenteral hepcidin substitution therapy in mice. Br J Nutr 2012; 108: 1723-1725
41. McDonald CJ, Wallace DF, Ostini L, et al. Parenteral vs oral iron: Influence on hepcidin signaling pathways though analysis of Hfe/Tfr2 null mice.AmJ Physiol Gastrointest Liver Physiol 2013; 306: G132-G139
42. Ma J, Wen X, Mo F, et al. Effects of different doses and duration of iron supplementation on curing iron deficiency anemia: an experimental study. Biol Trace Elem Res 2014; 162: 242-251
43. Laftah AH, Ramesh B, Simpson RJ, et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103: 3940-3944
44. Drüeke TB. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant 2002; 17 (Suppl 2): 13-16
45. Hazell T, Johnson IT. In vitro estimation of iron availability from a range of plant foods: influence of phytate, ascorbate and citrate. Br J Nutr 1987; 57: 223-233
46. Zhang H, Onning G, Oste R, et al. Improved iron bioavailability in an oatbased beverage: the combined effect of citric acid addition, dephytinization and iron supplementation. Eur J Nutr 2007; 46: 95-102
47. Palika R, Mashurabad PC, Kilari S, et al. Citric acid mediates the iron absorption from low molecular weight human milk fractions. J Agric Food Chem 2013; 61: 11151-7
48. Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36: 949-953.
49. Stewart WB, Yuile CL, Claiborne HA, et al. Radioiron absorption in anemic dogs; fluctuations in the mucosal block and evidence for a gradient of absorption in the gastrointestinal tract. J Exp Med 1950; 92: 375-382
50. Schmann K, Elsenhans B, Ehtechami C, et al. Rat intestinal iron transfer capacity and the longitudinal distribution of its adaptation to iron deficiency. Digestion 1990; 46: 35-45
51. Takeuchi K, Bjarnason I, Laftah AH, et al. Expression of iron absorption genes in mouse large intestine. Scand J Gastroenterol 2005; 40: 169-177
52. Frazer DM, Wilkins SJ, Anderson GJ. Elevated iron absorption in the neonatal rat reflects high expression of iron transport genes in the distal alimentary tract. Am J Physiol Gastrointest Liver Physiol 2007; 293: G525-G531
53. Johnston KL, Johnson DM, Marks J, et al. Non-haem iron transport in the rat proximal colon. Eur J Clin Invest 2006; 36: 35-40
54. Koskenkorva-Frank TS, Weiss G, Koppenol WH, et al. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med 2013; 65: 1174-1194
55. Carrier J, Aghdassi E, Platt I, et al. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001; 15: 1989-1999
56. Brissot P, Ropert M, Le Lan C, et al. Non-Transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012; 1820: 403-410
57. Chua AC, Klopcic B, Lawrance IC, et al. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol 2010; 16: 663-672